The phosphorylation status of PIP5K1C at serine 448 can be predictive for invasive ductal carcinoma of the breast

Nisha Durand; Sahra Borges; Tavia Hall; Ligia Bastea; Heike Döppler; Brandy H. Edenfield; Aubrey E. Thompson; Xochiquetzal Geiger; Peter Storz

doi:10.18632/oncotarget.26357

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

The phosphorylation status of PIP5K1C at serine 448 can be predictive for invasive ductal carcinoma of the breast

Nisha Durand, Sahra Borges, Tavia Hall, Ligia Bastea, Heike Döppler, Brandy H. Edenfield, Aubrey E. Thompson, Xochiquetzal Geiger and Peter Storz _

PDF | HTML | Supplementary Files | How to cite | Press Release

Oncotarget. 2018; 9:36358-36370. https://doi.org/10.18632/oncotarget.26357

Metrics: PDF 1557 views | HTML 2432 views | ?

Abstract

Nisha Durand1, Sahra Borges1, Tavia Hall1, Ligia Bastea1, Heike Döppler1, Brandy H. Edenfield1, E. Aubrey Thompson1, Xochiquetzal Geiger2 and Peter Storz1

1Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville, FL 32224, USA

2Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL 32224, USA

Correspondence to:

Peter Storz, email: [email protected]

Keywords: PIP5K1C; breast cancer; invasive phenotype; phosphorylation

Received: June 09, 2018 Accepted: October 31, 2018 Published: November 20, 2018

ABSTRACT

Phosphatidylinositol-4-phosphate 5-kinase type-1C (PIP5K1C) is a lipid kinase that regulates focal adhesion dynamics and cell attachment through site-specific formation of phosphatidylinositol-4,5-bisphosphate (PI4,5P₂). By comparing normal breast tissue to carcinoma in situ and invasive ductal carcinoma subtypes, we here show that the phosphorylation status of PIP5K1C at serine residue 448 (S448) can be predictive for breast cancer progression to an aggressive phenotype, while PIP5K1C expression levels are not indicative for this event. PIP5K1C phosphorylation at S448 is downregulated in invasive ductal carcinoma, and similarly, the expression levels of PKD1, the kinase that phosphorylates PIP5K1C at this site, are decreased. Overall, since PKD1 is a negative regulator of cell migration and invasion in breast cancer, the phosphorylation status of this residue may serve as an indicator of aggressiveness of breast tumors.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26357

Publication Alerts

Research Papers:

The phosphorylation status of PIP5K1C at serine 448 can be predictive for invasive ductal carcinoma of the breast

Abstract